AngioDynamics (ANGO) Reports In-Line Q4 EPS, Offers Guidance

AngioDynamics (NASDAQ: ANGO) reported Q4 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $87 million versus the consensus estimate of $82.92 million.

GUIDANCE:

AngioDynamics sees FY2023 EPS of $0.01-$0.06, versus the consensus of $0.08. AngioDynamics sees FY2023 revenue of $342-348 million, versus the consensus of $338 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• AngioDynamics (ANGO) PT Raised to $19 at H.C. Wainwright
• UnitedHealth Group (UNH) Tops Q2 EPS by $1.53, Beats on Revenue; Offers FY26 EPS Guidance
• VIST Financial Corp. (VIST) Misses Q2 EPS by 76c